DUBAI, UNITED ARAB EMIRATES--(Marketwire -08/13/12)- NewBridge Pharmaceuticals, a specialty therapeutics company focused on pharmaceuticals, biologics, diagnostics and medical devices serving the AfMET region (Middle East, Africa, Turkey & Caspian regions), today announced that the company has established an exclusive agreement with Genomic Health, Inc. (GHDX), a global health company that provides actionable genomic information to personalize genomic health decisions, to provide the Oncotype DX® test in the NewBridge's core strategic territoriesin the Middle East, Africa, and Caspian regions. As part of this agreement, NewBridge will be able to offer the Oncotype DX tests for treatment of patients with early-stage, estrogen-positive (ER+) invasive breast cancer, DCIS (ductal carcinoma in situ of the breast), as well as colon cancer patients with stage II and stage III disease.
"Breast cancer is the most common cancer in Arab women, constituting up to 42 percent of all cancers in women, and it presents itself almost 10 years earlier in comparison to women affected by breast cancer in the US and Europe," said Joe Henein, president and chief executive officer, NewBridge Pharmaceuticals. "While facing a very difficult decision about chemotherapy treatment, the Oncotype DX test can help women with ER+, node negative or DCIS breast cancer make the treatment decision that is right for them. In addition, as colon cancer rates are also high in the region, we are pleased to provide Oncotype DX Colon Cancer, a diagnostic test that can help determine the likelihood of colon cancer returning after surgery in patients who are considering chemotherapy. We are delighted to enter into this exclusive partnership with Genomic Health, a world leader in developing multi-gene tests for cancer patients."
Traditionally, doctors have used traditional cancer characteristics such as tumor size, grade and lymph node status to assess how likely cancer is to recur. While these characteristics are still helpful in choosing a course of treatment, the additional genomic information provided by the Oncotype DX® test helps physicians and patients determine a more personalized treatment plan based on a patient's individual tumor biology.
"Licensing Genomic Health's innovative molecular test underpins our long-term strategic mission to bridge the access gap and bring new technologies into the AfMET region to serve the unmet medical needs of our patients," said Garrett Vygantas, M.D., vice president of business development and licensing, NewBridge. "A genomic test like Oncotype DX has an important role to play in improving treatment decision making and ultimately impacting on quality of care."
About the Oncotype DX® Breast Cancer Test
The multi-gene Oncotype DXtest has been shown to predict the risk of recurrence and likelihood of chemotherapy benefit in invasive breast cancer and predict the likelihood of recurrence in pre-invasive breast cancer or ductal carcinoma in situ (DCIS). The test can help patients and their doctors determine the most likely progression of the disease in order to make more informed decisions about their individual treatment. Multiple studies from different countries have shown that the knowledge of the Oncotype DX test's Recurrence Score® result changes physician treatment recommendations in about 30 percent of their early-stage, ER+ invasive breast cancer patients.
About the Oncotype DX® Colon Cancer Test
The Oncotype DX colon cancer test is a clinically validated multi-gene test that can help men and women with stage II and stage III colon cancer learn more about the biological features of their specific tumor by indicating the likelihood that a patient's cancer may return in the future. Coupled with other pieces of information, the results from the Oncotype DX test can help patients and their doctors make personalized decisions about whether or not to include chemotherapy in their treatment plan.
"All of our products have been developed based on rigorous science, and the growing body of evidence demonstrates the clinical utility and cost effectiveness of the Oncotype DXtest across countries and healthcare systems," said Peter Zuendorf, vice president, International Sales and Marketing in Europe, Middle East and Africa, Genomic Health. "This agreement reinforces how the Oncotype DX test can help physicians worldwideuse their patients' tumor biology to go beyond the traditional clinical and pathologic factors to establish a more appropriate treatment plan for an individual patient."
About NewBridge Pharmaceuticals
NewBridge Pharmaceuticals is a specialty therapeutics company focused on pharmaceuticals, biologics, and medical diagnostics serving the AfMET markets (Middle East, Africa, Turkey, and Caspian regions) to address the unmet medical needs of diseases with high regional prevalence. Headquartered in UAE with strong local and international business network, NewBridge is uniquely positioned as the partner-of-choice for companies seeking to create value for their pharma or medical products in the high growth emerging AfMET markets.
For more information, please visit www.nbpharma.com.
About Genomic Health
Genomic Health, Inc. (GHDX) is a global health company that provides actionable genomic information to personalize genomic health decisions. The company's lead product, the Oncotype DX(r) breast cancer test, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer and has been shown to predict the likelihood of recurrence in ductal carcinoma in situ (DCIS). In addition to this widely adopted test, Genomic Health provides the Oncotype DX colon cancer test, the first multi-gene expression test developed for the assessment of risk of recurrence in patients with stage II disease and appropriate stage III patients. As of June 30, 2012, more than 10,000 physicians in over 65 countries had ordered more than 295,000 Oncotype DX tests. Genomic Health has a robust pipeline focused on developing tests to optimize the treatment of prostate and renal cell cancers, as well as additional treatment decisions in breast and colon cancers. The company is based in Redwood City, California with European headquarters in Geneva, Switzerland. For more information, please visit, www.GenomicHealth.com. To learn more about Oncotype DX tests, visit: www.OncotypeDX.com and www.mybreastcancertreatment.org.
- Oncotype DX
- colon cancer
- Breast cancer